<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Hedge Fund News From HedgeCo.Net &#187; diabetes drug</title>
	<atom:link href="http://www.hedgeco.net/news/tag/diabetes-drug/feed" rel="self" type="application/rss+xml" />
	<link>http://www.hedgeco.net/news</link>
	<description>Breaking Hedge Fund News</description>
	<lastBuildDate>Mon, 13 Feb 2012 16:50:25 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.2.1</generator>
		<item>
		<title>Eastbourne Proposes Amylin Directors, Backs Icahn</title>
		<link>http://www.hedgeco.net/news/02/2009/eastbourne-proposes-amylin-directors-backs-icahn.html</link>
		<comments>http://www.hedgeco.net/news/02/2009/eastbourne-proposes-amylin-directors-backs-icahn.html#comments</comments>
		<pubDate>Tue, 03 Feb 2009 00:00:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Syndicated]]></category>
		<category><![CDATA[acquisition]]></category>
		<category><![CDATA[amylin pharmaceuticals inc]]></category>
		<category><![CDATA[byetta]]></category>
		<category><![CDATA[capital-management-llc]]></category>
		<category><![CDATA[carl-icahn]]></category>
		<category><![CDATA[confidence]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[diabetes drug]]></category>
		<category><![CDATA[investor]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[oct 5]]></category>
		<category><![CDATA[s board]]></category>
		<category><![CDATA[san diego]]></category>
		<category><![CDATA[slate]]></category>
		<category><![CDATA[stock]]></category>
		<category><![CDATA[third-party]]></category>

		<guid isPermaLink="false"></guid>
		<description><![CDATA[Bloomberg &#8211; Hedge fund Eastbourne Capital Management LLC nominated five directors to the board of Amylin Pharmaceuticals Inc. and is supporting a slate put forward by investor Carl Icahn, after it &#8220;lost confidence&#8221; in leadership of the maker of the Byetta diabetes drug. Eastbourne, which owns 12.5 percent of San Diego-based Amylin, said in a [...]]]></description>
		<wfw:commentRss>http://www.hedgeco.net/news/02/2009/eastbourne-proposes-amylin-directors-backs-icahn.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

<!-- Performance optimized by W3 Total Cache. Learn more: http://www.w3-edge.com/wordpress-plugins/

Page Caching using disk: enhanced
Database Caching 1/9 queries in 0.307 seconds using disk: basic
Object Caching 196/218 objects using disk: basic

Served from: www.hedgeco.net @ 2012-02-13 14:35:47 -->
